PTPrzemyslaw Twardowski

Przemyslaw Twardowski

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Przemyslaw Twardowski has a total of 103 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Randomized phase II trial of sipuleucel-T immunotherapy preceded by sensitizing radiation therapy and sipuleucel-t alone in patients with metastatic castrate resistant prostate cancer.

    by Przemyslaw Twardowski, Jeffrey Y.C. Wong, Sumanta K. Pal, Paul Henry Frankel, Kelly Franklin, Maribel Junqueira, Manisha R. Prajapati, Deborah Harwood, Neeraj Agarwal

    222 Background: Sipuleucel-T (sip-T) is an autologous cellular vaccine indicated for patients (pts) with asymptomatic or minimally symptomatic metastatic castration resistant prostate cancer (mCRPC). Since radiation therapy (RT) can suppress the bone marrow function and immune response, previous studies evaluating sip-T excluded pts who received RT less than or equal to 28 days prior to sip-T therapy. Recent evidence suggests that RT may act synergistically with immunotherapy to enhance and broaden antitumor immune response. Methods: Pts who met standard criteria for sip-T were randomized to receive sip-T alone (Arm A) or sip-T initiated 1 week after completing sensitizing RT to single metastatic site (Arm B). RT was delivered at 300cGy/day to 3000 cGy total. The primary endpoint was the ability to safely combine sip-T preceded by RT and generate sip-T product with adequate immune activation parameters. Secondary endpoints included the measurement of immune responses to prostatic acid phosphatase (PAP) and PA20204 (recombinant fusion protein utilized in the generation of sip-T). Results: 51 pts were enrolled, 2 did not receive any sip-T because of vascular access problems and were excluded. 24 were treated on Arm A, 25 on Arm B. 47/49 pts received all 3 sip-T infusions. Median age was 66 yrs (range 45-90). Sip-T product parameters including: total nucleated cell (TNC) count, antigen presenting cell (APC) count and APC activation were similar in both groups. 2 pts on Arm A demonstrated PSA response. Median progression free survival (PFS) was 3.0 months on Arm A and 4.6 months on Arm B (p = 0.19). Both arms showed similar increases in humoral responses to PA2024 and PAP. IFN-ƴ ELISPOT T-cell activation responses to PA20204 were observed in both arms, but were more robust in the Arm A (p = 0.04). Both arms were well-tolerated, with fatigue as the most common grade 2 adverse event (1 pt in Arm A and 3 pts in Arm B). Conclusions: Sensitizing RT completed 1 week before generation of sip-T did not affect product parameters and the ability to deliver sip-T therapy. RT did not enhance the humoral and cellular responses associated with sip-T therapy. Clinical trial information: NCT01807065.


  • Genetic polymorphisms to predict progression-free survival in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving abiraterone therapy: Results from the NCI 9012 trial.

    by Costantine Albany, Stephanie Daignault-Newton, Todd C Skaar, Joseph Ipe, Javed Siddiqui, Przemyslaw Twardowski, Mark N. Stein, Lakshmi Priya Kunju, Arul M. Chinnaiyan, Robert B. Montgomery, et al.

    145 Background: Abiraterone is a CYP17 inhibitor approved for treatment of men with mCRPC. The NCI 9012 trial evaluated abiraterone alone with or without the PARP inhibitor veliparib in mCRPC patients. We hypothesized that germline genetic variation in the androgen axis and other metabolic enzymes would predict response to veliparib + abiraterone vs. abiraterone alone. Methods: A randomized trial cohort of (148) men with advanced mCRPC treated with abiraterone with or without veliparib was genotyped for 120 DNA polymorphisms in genes involved in androgen metabolism using Lifetech Open array chips. Blood for pharmacogenomic SNP analysis were collected at pre-treatment from each subject into 10-mL EDTA tube. Polymorphisms were tested using Cox models without treatment for prognostic testing and with treatment arm for predictive testing. Results: Genotyping was completed in 143 of 148 men; all were treated with abiraterone; 72 without veliparib (Median PFS: 10.3m) and 71 with veliparib (Median PFS: 11.3m). Polymorphisms in separate genes (SLCO2B1, KIF3C CYP19A, ESR1) were significantly (P ≤ .025) associated with progression-free survival (PFS) during abiraterone (q-value < 0.69). Polymorphisms in (CYP11A1, HSD17B4, ABHD13;LIG4, CYP19A1, HSD17B4, TRMT11) were predictive for PFS in patients treated with combination of abiraterone/veliparib compared to abiraterone alone (p-value < 0.025; q-value < 0.28). Conclusions: This analysis examines the influence of inherited variations on the efficacy of abiraterone, establishing the importance of pharmacogenomics on individual’s response to this therapy. Genotyping patients at these loci could be predictive of improved PFS to valiparib in combination with abiraterone. Further analysis of the association of more than one polymorphisms compared to zero or one with PFS associated with improved TTP demonstrated a better response to therapy than individuals carrying zero or one is ongoing. Clinical trial information: NCT01576172.

  • Circulating tumor cells (CTCs) in SWOG S1216: A phase 3 multicenter trial in metastatic hormone sensitive prostate cancer (mHSPC).

    by Amir Goldkorn, Melissa Plets, Neeraj Agarwal, Maha Hussain, Primo Lara, Daniel A. Vaena, Gary R. MacVicar, Tony Crispino, Andrea Lynne Harzstark, Przemyslaw Twardowski, et al.

    11516 Background: Novel hormonal therapies recently approved for metastatic castration resistant prostate cancer (mCRPC) are now being tested in hormone sensitive disease (mHSPC), prompting evaluation of new biomarkers to guide therapy in this earlier disease state. We are conducting CTC enumeration, sequencing, and gene expression studies in S1216, a SWOG-sponsored North American Intergroup phase 3 trial of androgen deprivation in combination with bicalutamide or orteronel, a CYP17,20 lyase inhibitor. Baseline CTC enumeration data are presented for 225 patients evaluated to date. Methods: Four 7.5mL tubes of blood are collected for CTC analysis (enumeration, sequencing, gene expression) at study entry and at progression to mCRPC. Specimens are logged in the SWOG online specimen tracking system and sent overnight at room temperature to a central site (Goldkorn Lab) for analysis. One of the 4 tubes is a CellSave tube used for CTC enumeration on the FDA-cleared CellSearch platform (Janssen/J&J). CellSearch CTC counts are transmitted to SWOG Statistical Center for analysis and correlation with clinical data. Results: From 11/2014 - 10/2015, CTCs were detected in 78 of 211 evaluable samples (37%), and detection was impacted by whether patients had already initiated therapy at the time of sample collection (29% detection in treated vs. 46% in treatment naïve, p=0.01). Median CTC count for patients with detectable CTCs was 2/7.5 ml blood (1st quartile =1, 3rdquartile =9), and median for the entire cohort was 0 (range 0-4000). Presence of baseline CTCs was associated with higher PSA (p=0.03), bony metastases (p=0.05), presence of extensive disease (p1/3 of patients and nearly half of patients who had not yet initiated therapy. Presence of CTCs wasassociated with known baseline prognostic factors and therefore may predict clinical outcome with continued follow-up. Further CTC enumeration, sequencing and gene expression are ongoing in S1216 to maximize the prognostic and predictive benefit of CTC analysis in mHSPC. Clinical trial information: NCT01809691.


  • Validation of the association of RECIST 1.0 changes with survival in men with metastatic castration-resistant prostate cancer (mCRPC) treated on SWOG Study S0421.

    by Gregory Russell Pond, Guru Sonpavde, Melissa Plets, Catherine M. Tangen, Maha Hussain, Primo Lara, Amir Goldkorn, Mark Garzotto, Philip C. Mack, Celestia S. Higano, et al.

    5079 Background: Prostate specific antigen (PSA) and bone scan changes are often used as components of primary endpoints in phase II trials of mCRPC. However, they do not reliably capture drug activity, as suggested by multiple phase III trials that failed to validate promising activity in phase II trials. Recently, an association between RECIST 1.0 changes and overall survival (OS) in men with mCRPC receiving docetaxel was observed. We externally validated the prognostic impact of RECIST 1.0 changes on OS. Methods: S0421 was a phase III trial in men with mCRPC men treated with docetaxel and prednisone plus either placebo or atrasentan. Individual patient data from both arms of were combined for analysis since no differences in outcomes were observed. Cox proportional hazards regression evaluated the association of RECIST outcomes within 120 days, i.e. unconfirmed partial response (PR), stable disease (SD) and progressive disease (PD) with OS from day 120. The analysis was adjusted for selected major baseline prognostic factors: hemoglobin, alkaline phosphatase, PSA, treatment arm, performance status, visceral disease, progression type, pain and Gleason score. All tests were two-sided and P ≤ 0.05 was considered statistically significant. Results: Of 1038 eligible patients on S0421, 469 had measurable disease. Of these, 377 had RECIST assessments within 120 days after starting therapy. From day 120, 23 patients had PD, 230 had SD, and 73 had ≥ PR (n = 73). Median OS of was 7.1, 13.4 and 16.3 months, respectively (p = 0.004). After adjusting for baseline factors, RECIST changes remained significantly associated with OS (p = 0.002). For every 10% increase in lesion size, the hazard of dying after day 120 increased by 6.3% (95% CI: 2.3% to 10.5%, p = 0.0018), after adjusting for prognostic factors. Conclusions: This analysis provides external validation of the association of RECIST 1.0 changes with OS in men with mCRPC receiving docetaxel-based chemotherapy. Given that current imaging is increasingly detecting measurable disease, a robust and objective signal of activity represented by RECIST changes should be shown in phase II trials before launching phase III trials.

  • Open Access

    A phase I trial of mushroom powder in patients with biochemically recurrent prostate cancer: Roles of cytokines and myeloid‐derived suppressor cells for Agaricus bisporus–induced prostate‐specific antigen responses

    by Przemyslaw Twardowski, Noriko Kanaya, Paul Frankel, Timothy Synold, Christopher Ruel, Sumanta K. Pal, Maribel Junqueira, Manisha Prajapati, Tina Moore, Pamela Tryon, et al.

    BACKGROUND: Each year in the United States, nearly 50,000 prostate cancer patients exhibit a rise in prostate‐specific antigen (PSA) levels, which can indicate disease recurrence. For patients with biochemically recurrent prostate cancer, we evaluated the effects of white button mushroom (WBM) powder on serum PSA levels and determined the tolerability and biological activity of WBM.METHODS: Patients with continuously rising PSA levels were enrolled in the study. Dose escalation was conducted in cohorts of 6; this ensured that no more than 1 patient per cohort experienced dose‐limiting toxicity (DLT). The primary objective was to evaluate treatment feasibility and associated toxicity. The secondary objectives were to determine WBM's effect on serum PSA/androgen levels; myeloid‐derived suppressor cells (MDSCs); and cytokine levels.RESULTS: Thirty‐six patients were treated; no DLTs were encountered. The overall PSA response rate was 11%. Two patients receiving 8 and 14 g/d demonstrated complete response (CR): their PSA declined to undetectable levels that continued for 49 and 30 months. Two patients who received 8 and 12 g/d experienced partial response (PR). After 3 months of therapy, 13 (36%) patients experienced some PSA decrease below baseline. Patients with CR and PR demonstrated higher levels of baseline interleukin‐15 than nonresponders; for this group, we observed therapy‐associated declines in MDSCs.CONCLUSIONS: Therapy with WBM appears to both impact PSA levels and modulate the biology of biochemically recurrent prostate cancer by decreasing immunosuppressive factors. Cancer 2015;121:2942–2950. © 2015 American Cancer Society.


  • Emerging Agents in Renal Cell Carcinoma

    by Sumanta Kumar Pal, David Y. Josephson, Przemyslaw Twardowski, David I. Quinn

  • Papillary Renal Cell Carcinoma: Current Progress and Future Directions

    by Przemyslaw W. Twardowski, Philip C. Mack, Primo N. Lara


  • A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy

    by Przemyslaw W. Twardowski, Jan H. Beumer, C.S. Chen, Andrew S. Kraft, Gurkamal S. Chatta, Masato Mitsuhashi, Wei Ye, Susan M. Christner, Michael B. Lilly

    There is a need for efficacious therapies for metastatic castration-resistant prostate cancer (mCRPC) after disease progression on docetaxel. The SRC tyrosine kinase and its related family members may be important drivers of prostate cancer and can be inhibited by dasatinib. mCRPC patients, after one previous chemotherapy, started dasatinib at 70 mg twice daily, amended to 100 mg daily. The primary endpoint was the disease control (DC) rate, defined as complete response (CR), partial response (PR), or stable disease (SD) in prostate specific antigen (PSA), RECIST, bone scan, and FACT-P score. Up to 41 patients were to be accrued (two-stage design, 21+20) to rule out a null-hypothesized effect of 5 versus 20% (α=0.05, β=0.1). Secondary endpoints included progression-free survival, toxicity, and pharmacokinetic and pharmacodynamic correlatives. Of 38 patients, 27 were evaluable for response or toxicity. The median duration of therapy was 55 days (6–284). Five patients showed DC after 8 weeks of therapy (18.5% DC, 95% CI: 6.3–38.1%). One PR (3.7% response rate, 95% CI: 0.1–19.0%) was observed in a patient treated for 284 days. Twelve patients (43%) discontinued treatment for toxicity. Dasatinib induced a decrease in phytohemagglutinin-stimulated CSF2, CD40L, GZMB, and IL-2 mRNAs in blood cells, indicating target engagement. Decreases in plasma IL-6 and bone alkaline phosphatase, and in urinary N-telopeptide, were associated with DC. Dasatinib has definite but limited activity in advanced mCRPC, and was poorly tolerated. The observation of a patient with prolonged, objective, clinically significant benefit warrants molecular profiling to select the appropriate patient population.


  • A phase Ib trial of mushroom powder in biochemically recurrent, hormone-naive prostate cancer.

    by Przemyslaw Twardowski, Paul Henry Frankel, Sumanta Kumar Pal, Timothy W. Synold, Christopher Ruel, Maribel Junqueira, Tina Nguyen, Melanie R. Palomares, Pamela Renee Tryon, Shiuan Chen

    142 Background: Biochemically recurrent prostate cancer (PC) is a common presentation of relapse after primary local therapies. Strategies to delay disease progression and defer initiation of androgen deprivation therapy and associated side effects are needed. White button mushroom (WBM, Agaricus bisporus) extract suppresses prostate cancer tumor growth in animals, and prior human experience indicates favorable toxicity profile. Methods: Patients (pts) with rising PSA of ≥0.2 ng/mL after prostatectomy (RP) and/or radiation (RT) and no radiographic evidence of metastases were treated with WBM powder tablets at 4, 6, 8, 10, 12 and 14 grams po daily. Dose escalation was conducted in cohorts of 6 and continued as long as no more than 1 patient per cohort experienced dose limiting toxicity (DLT). Therapy continued until PSA increased by ≥100% and by ≥1 ng/mL, or clinically detectable metastases or unacceptable toxicity occurred. Primary objective was feasibility and toxicity, secondary objective was the effect of WBM on serum PSA and androgen levels. Results: Thirty six pts were treated. Median age was 68 (53-80).Thirty three pts (92%) had prior RP and all underwent previous RT. Median PSA was 1.9 (0.2-22.2). Mean compliance was 98.6 %. No DLT’s were encountered. The most common side effect was grade 1 abdominal bloating (39%); one patient experienced asymptomatic grade 3 hyponatremia. Overall PSA response rate was 11% (95% CI: 4%-27%). Two pts receiving 8 and 14 gm/day demonstrated a PSA complete response (CR), defined as a decline in PSA to undetectable levels that continues for 26 and 7 months respectively. Two pts, receiving 8 and 14 gm/day, experienced confirmed PSA partial responses (PR), defined as a ≥50% PSA decline on treatment. After 3 months of therapy 36% of pts (13/36) demonstrated some PSA decrease below baseline. No association between PSA response and serum testosterone, DHT or DHEA levels was observed. Median duration on therapy is 10.2 months (0.9 – 35.3). Ten pts remain on therapy. Conclusions: Therapy with WBM was well tolerated. Our data suggest that WBM intake results in durable decreases in PSA level in some patients with biochemically recurrent PC. Further studies to clarify mechanism of action are warranted. Clinical trial information: NCT00779168.


  • Emerging Agents in Renal Cell Carcinoma

    by Sumanta Kumar Pal, David Y. Josephson, Przemyslaw Twardowski, David I. Quinn